Urea glucokinase activators
View Patent ↗This application relates to novel urea glucokinase activators and use of the compounds of the invention for preparation of a medicament for the treatment of various diseases, e.g. for the treatment of type 2 diabetes. Further encompassed is a pharmaceutical composition comprising a compound according to the invention and a process for preparing such.
1. A compound selected from the group consisting of
2-Methyl-2-{2-[3-(trans-4-methyl-cyclohexyl)-3-(4-phenyl-butyl)-ureido]-thiazol-5-ylsulfanyl}-propionic acid; and
2-{2-[3-[2-(3,4-Dimethoxy-phenyl)-ethyl]-3-(trans-4-methyl-cyclohexyl)-ureido]-thiazol -5-ylsulfanyl}-2-methyl-propionic acid;
or a pharmaceutically acceptable salt thereof.
2. A compound of claim 1 , which compound is:
2-Methyl-2-{2-[3-(trans-4-methyl-cyclohexyl)-3-(4-phenyl-butyl)-ureido]-thiazol-5-ylsulfanyl}-propionic acid or a pharmaceutically acceptable salt thereof.
3. A compound of claim 1 , which compound is:
2-{2-[3-[2-(3,4-Dimethoxy-phenyl)-ethyl]-3-(trans-4-methyl-cyclohexyl)-ureido]-thiazol -5-ylsulfanyl}-2-methyl-propionic acid or a pharmaceutically acceptable salt thereof.
4. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.
5. A pharmaceutical composition comprising a compound according to claim 2 and a pharmaceutically acceptable carrier.
6. A pharmaceutical composition comprising a compound according to claim 3 and a pharmaceutically acceptable carrier.